Ovid Therapeutics Announces Appointment Of Highly-Ranked Biotechnology Research Analyst Dr. Yaron Werber As Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Ovid Therapeutics Inc. (Ovid), a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, today announced the appointment of Yaron Werber, M.D., MBA, to the position of Chief Financial Officer, replacing interim CFO Mark Feldberg, who will continue in his role at TradeLink. With nearly 15 years of experience as a highly-ranked biotechnology research analyst at marquee Wall Street firms, Dr. Werber brings a distinguished track record of success to Ovid. He will join effective June 22, 2015, and will report to Dr. Jeremy Levin, Chief Executive Officer and Chairman of Ovid. Dr. Werber will be responsible for all financial planning and reporting, will head investor and public relations, and will support Ovid's business development initiatives.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.

A month after seeing a "robust immune response" from a clutch of RSV vaccine hopefuls, GlaxoSmithKline is kicking off a key late-stage test.